Opthea Limited (OPT)
NASDAQ: OPT · Real-Time Price · USD
3.410
0.00 (0.00%)
At close: Oct 8, 2025
Company Description
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States.
The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).
It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Opthea Limited
| Country | Australia |
| Founded | 1984 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jeremy Levin |
Contact Details
Address: Level 9, 505 Little Collins Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9826 0399 |
| Website | opthea.com |
Stock Details
| Ticker Symbol | OPT |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $13.50 |
| CIK Code | 0001815620 |
| CUSIP Number | 68386J208 |
| ISIN Number | US68386J2087 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer |
| Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder and Chief Innovation Officer |
| Karen Adams CPA | Vice President of Finance and Company Secretary |
| Thomas Charles Reilly | Chief Financial Officer |
| Kevin Bitter | Vice President of Strategy and Corporate Development |
| Anand Sundaram | Vice President Marketing |
| Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Julie Clark M.D., M.S. | Senior Vice President of Clinical Development |
| Dr. Arshad M. Khanani M.A., M.D. | Chief Medical Advisor and Chairman of Medical Advisory Board |
| Jen Watts | Vice President Global Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 6, 2025 | 6-K | Report of foreign issuer |
| Sep 15, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Sep 15, 2025 | 6-K | Report of foreign issuer |
| Aug 29, 2025 | 6-K | Report of foreign issuer |
| Aug 20, 2025 | 6-K | Report of foreign issuer |
| Aug 19, 2025 | 6-K | Report of foreign issuer |
| Aug 19, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| Apr 10, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 6-K | Report of foreign issuer |